Supplier News: MilliporeSigma, Cytiva & Nanopharm

The latest from CDMOs, CMOs, and suppliers featuring MilliporeSigma, Cytiva, Nanopharm and Schott.

Biologics Mfg
* MilliporeSigma Opens Biomanufacturing Facility in France
* Cytiva Acquires Viral Vector Mfg Provider Cevec Pharmaceuticals
Formulation Development/Drug Product Manufacturing

* Nanopharm, Fluidda in Technology Pact for Orally Inhaled Generic Products
Packaging
* Schott To Expand Cartridge Mfg Capacity in China & Hungary


Biologics Mfg

MilliporeSigma Opens Biomanufacturing Facility in France
MilliporeSigma, the life science business of Merck KGaA, has opened a 2,700-square-meter commercial manufacturing facility at the company’s site in Martillac, France to expand production capacity for monoclonal antibodies and other recombinant proteins. The facility can produce 200 to 2,000 liters of drug substance and features two 2,000-liter bioreactors.

Source: MilliporeSigma


Cytiva Acquires Viral Vector Mfg Provider Cevec Pharmaceuticals
Cytiva has completed its acquisition of Cevec Pharmaceuticals, a Köln, Germany-based provider of cell line development and viral vector manufacturing technologies.

Cevec brings scalable producer cell lines for vectors based on adeno-associated virus and adenovirus. With the technology, all components necessary for vector production are integrated into the genome of the producer cell line to provide an alternative to technologies based on transfection or the use of a helper virus.

Source: Cytiva


Formulation Development/Drug Product Manufacturing

Nanopharm, Fluidda in Technology Pact for Orally Inhaled Generic Products
Nanopharm, an Aptar Pharma company and a contract provider of preclinical, formulation development, and analytical testing services, has formed an exclusive collaboration with Fluidda, a specialist in functional respiratory imaging, to provide expertise for the development of orally inhaled generic products via the alternative bioequivalence pathway of the US Food and Drug Administration (FDA). Nanopharm was acquired by Aptar in 2019, as part of Aptar’s strategy to expand its services offerings and partner with pharmaceutical companies earlier in the drug-development process.

Nanopharm has expertise in developing generic orally inhaled generic products for asthma and chronic obstructive pulmonary disease via FDA’s alternative bioequivalence pathway using its proprietary in vitro and in silico service platform, SmartTrack. Fluidda’s proprietary in silico platform FRI (Functional Respiratory Imaging) provides quantitative predictions of regional drug deposition in disease-state lungs using computational fluid dynamics. The FRI platform provides information to help understand the availability and activity of the drug at the site of action in the lungs, when complemented by Nanopharm’s local lung physiologically-based pharmacokinetic model platform and its in vitro data.

Source: Nanopharm


Packaging

Schott To Expand Cartridge Mfg Capacity in China & Hungary
Schott Pharma, the pharmaceutical business of Schott, has announced plans to expand its manufacturing facilities in China and Hungary to increase its production capacity for cartridges. The expansion would be supported with a double-digit-million euro investment to allow the company to advance its forming technology and online inspection systems.

Source: Schott Pharma